Sunday Edition: Sodium

Colorado will receive nearly $2 million from Abbott Laboratories as part of a $348 million settlement over allegations of misrepresenting the safety of its infant formula, with additional $35.5 million to be split among states. The lawsuit claimed Abbott failed to maintain safety standards and disclose contamination test results. The funds will be returned to Colorado's Medicaid program.

Abbott Laboratories (ABT) will pay $384 million to settle a lawsuit alleging it failed to maintain safety standards in its baby formula manufacturing facilities from 2018 to 2022, according to New York Attorney General Letitia James. The settlement includes $348 million to the federal government and $35 million to a coalition of states, with New York receiving $9.3 million. The lawsuit claimed Abbott's practices put products at risk of contamination and misled safety inspectors.

Abbott Laboratories (NYSE: ABT) reported Q2 2026 sales of $12.6B, up 13%, and raised its full-year adjusted EPS forecast to $5.45-$5.60. Analysts are bullish, citing growth in its Medical Devices segment and recent acquisitions. The stock has 21 'buy' ratings with target prices up to $143. Abbott's dividend history and growth prospects are key attractions for investors.

Abbott Laboratories agreed to pay $385 million to settle a DOJ lawsuit over contaminated baby formula. The DOJ alleged Abbott knowingly allowed the sale of contaminated formula and ignored safety issues at its Sturgis and Arizona factories. The settlement resolves claims from 2018 to 2022, with Abbott not admitting fault.

Abbott Laboratories will pay $384 million to resolve claims it sold potentially contaminated baby formula through Medicaid and WIC programs. New York will receive $9.3 million, with $5.3 million going directly to the state. The settlement follows a 2025 lawsuit alleging safety standard violations and misled inspections.

Abbott Laboratories agreed to a $385 million settlement over its 2022 recall of baby formula from its Michigan plant, which exacerbated a nationwide shortage. The settlement resolves claims from the DOJ, relators, and state attorneys general. Abbott denies fault or liability. The plant was closed due to contamination concerns but reopened by June 2022. The Biden administration took emergency measures to address the shortage.